Abstract
Therapeutic strategies using cytokines have not been extensively tested in patients with advanced non-small-cell lung cancer (NSCLC). We developed a basic laboratory and clinical research program to investigate the effective immunotherapeutic manipulations for activating the endogenous immune system with biological agents. Our efforts using low-dose interleukin 2 in conjunction with other biologic response modifiers for the treatment of NSCLC are summarized here.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Humans
-
Interleukin-2 / administration & dosage*
-
Lung Neoplasms / therapy*
-
Muromonab-CD3 / administration & dosage*
-
Tumor Necrosis Factor-alpha / administration & dosage*
Substances
-
Interleukin-2
-
Muromonab-CD3
-
Tumor Necrosis Factor-alpha